CureVac NV (WBO:CVAC) Long-Term Capital Lease Obligation : €35.55 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Long-Term Capital Lease Obligation?

CureVac NV's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €35.55 Mil.

CureVac NV's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (€36.58 Mil) to Dec. 2023 (€36.82 Mil) but then declined from Dec. 2023 (€36.82 Mil) to Mar. 2024 (€35.55 Mil).

CureVac NV's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€25.42 Mil) to Dec. 2022 (€37.11 Mil) but then declined from Dec. 2022 (€37.11 Mil) to Dec. 2023 (€36.82 Mil).

CureVac NV Long-Term Capital Lease Obligation Historical Data

The historical data trend for CureVac NV's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Long-Term Capital Lease Obligation Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

12.13

26.85

25.42

37.11

36.82

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															36.09	35.28	36.58	36.82	35.55

CureVac NV (WBO:CVAC) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

CureVac NV Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of CureVac NV's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.